When did REIG JOFRE publish its 2025 nine-month financial results, and what period do they cover?

REIG JOFRE published the results on 2025-11-05. They cover the first nine months of 2025 and compare revenue with the same period in 2024.

How did REIG JOFRE's revenue change in the first nine months of 2025?

REIG JOFRE reported revenue of €242 million, down 4% compared to the same period in 2024. On a like-for-like basis excluding the antibiotics portfolio, revenue was up 3%.

What were REIG JOFRE's reported and pro forma EBITDA figures for the first nine months of 2025?

Reported EBITDA reached €24 million, with a margin of 10%, while pro forma EBITDA reached €33 million, up 2%. The pro forma figure excludes the temporary capacity reduction in antibiotics, the effects of EMINTECH and other biotechnology developments.

Why was REIG JOFRE's reported EBITDA affected during the first nine months of 2025?

REIG JOFRE said reported EBITDA was affected by lower temporary production of antibiotics in Toledo during production improvements and adaptation to Annex 1 of the EU GMP. The reported figure includes the EMINTECH grant, with a net impact of €1.0 million.

What was REIG JOFRE's net income in the first nine months of 2025?

REIG JOFRE reported net income of €1.9 million. This included the contribution from equity-accounted affiliates, comprising 50% of Syna Therapeutics and 47% of Leanbio S.L. —up from 24% in 3Q25—.

How did REIG JOFRE's business units perform in the first nine months of 2025?

Specialty Pharmacare increased 1% and Consumer Healthcare increased 3%. These gains partially offset the impact on Pharmaceutical Technologies.

What operational changes is REIG JOFRE making in Toledo and Barcelona?

REIG JOFRE is carrying out an industrial ramp-up in Toledo and Barcelona. The company said recovery is expected from 2026 as new capacities come online.

What did REIG JOFRE report about its biotechnology activities and the EMINTECH grant?

REIG JOFRE reported the early collection of 100% of the IPCEI Med4Cure/EMINTECH grant, valued at €13M, and deeper integration of Leanbio within the group. The company is also vertically integrating biotechnological API production in the new facility under construction.

How important were international sales to REIG JOFRE's revenue in the first nine months of 2025?

International sales accounted for 58% of REIG JOFRE's total revenue. The company attributed this to commercial growth and the consolidation of its own brands.

What financial strength measures did REIG JOFRE report for the first nine months of 2025?

REIG JOFRE reported DFN/EBITDA of 2.1x, a gross margin of 61% and operating cash flow of €5.0 M. The company also reported a market capitalisation of €230 M.

What happened with REIG JOFRE's scrip dividend?

REIG JOFRE said 98% of shareholders chose to receive new shares under the scrip dividend. The company said this strengthened equity without impacting cash.

Where are REIG JOFRE's shares listed and what is the ticker symbol?

REIG JOFRE is listed on the Spanish stock market under the ticker BME:RJF.

What does REIG JOFRE say about its outlook from 2026 onwards?

REIG JOFRE said it is progressing according to its strategic plan and laying the foundations for progressive improvement in productivity and profitability from 2026 onwards. It also said recovery is expected from 2026 as new capacities come online.

Home
News Intelligence
Laboratorio Reig Jofre S.A.
REIG JOFRE reports €242 million revenue for first nine months of 2025

Back to all Laboratorio Reig Jofre S.A. press releases

Laboratorio Reig Jofre S.A.

BME:RJF

REIG JOFRE reports €242 million revenue for first nine months of 2025

Published Wednesday, 05 November 2025

Get alerts

Plain English summaries when Laboratorio Reig Jofre S.A. announces news.

At a glance

Company: Laboratorio Reig Jofre S.A.
Listings: BME:RJF
Announcement type: Financial results
Published: Wednesday, 05 November 2025
Reporting period: first nine months of 2025
Source announcement: reigjofre.com

Key figures
Measure	Figure	Period	Compared with
Revenues	€242 million	the first nine months of 2025	down 4% vs the same period in 2024
Reported EBITDA	€24 million	the first nine months of 2025	Not stated
Proforma EBITDA	€33 million	the first nine months of 2025	Not stated
Net income	€1.9 million	the first nine months of 2025	Not stated

Figures are quoted from this announcement and selected automatically.

FAQSIR Generated from this announcement View original release below for safe harbor and regulatory notices

Announcement Summary

REIG JOFRE (BME:RJF) published its financial results for the first nine months of 2025, reporting revenue, EBITDA and net income.

Revenue for 9M 2025 was €242 M (–4%), or +3% like-for-like excluding the antibiotics portfolio.
Reported EBITDA was €24 M, with a 10% margin and a €1.0 M net impact from the EMINTECH grant.
Pro forma EBITDA was €33 M (+2%), excluding temporary antibiotic capacity reduction, EMINTECH effects and other biotechnology developments.
Net income was €1.9 M, including 50% of Syna Therapeutics and 47% of Leanbio S.L., up from 24% in 3Q25.
The company expects recovery from 2026 as new capacities come online, following Toledo production improvements and EU GMP Annex 1 adaptation.

Specialty Pharmacare was +1% and Consumer Healthcare +3%; international sales were 58% of revenue. DFN/EBITDA was 2.1x, gross margin 61%, operating cash flow €5.0 M, and 98% of shareholders chose new shares under the Scrip Dividend.

Investor FAQs

REIG JOFRE reported €242M in revenue for the first nine months of 2025, alongside reported EBITDA of €24 M, pro forma EBITDA of €33 M and net income of €1.9 million. The company also reported progress in its industrial and biotech transformation, including industrial investments, operational optimisation and international expansion.

Source announcement

Company: Laboratorio Reig Jofre S.A.
Title: REIG JOFRE publishes its 2025 nine-months financial results
Published: Wednesday, 05 November 2025
Source site: reigjofre.com

Read the source announcement on reigjofre.com

FAQSIR's summary and investor FAQs are generated by AI from the text of this announcement alone, without information from other sources.

Figures, forecasts and other claims are the announcement's, not FAQSIR's. FAQSIR does not independently verify them.

Read the original press release

Full text as published, unedited.

Loading the original release…

Important Notice And Disclaimer

This article was generated by an artificial intelligence system from an announcement published by the issuer. It has not been independently researched, verified, or edited by a journalist, and no person holds editorial responsibility for its wording.

The issuer named in this article has not paid for this page and has no commercial relationship with its publisher. This is an unpaid evaluation preview produced from announcements the issuer published publicly, and it is not independent editorial coverage.

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

Ask about this announcement

Answers drawn only from this announcement

Reading the announcement…